Recent advances in the pharmacological control of energy balance and body weight

Annals of the New York Academy of Sciences

Volumn 827, Issue , 1997, Pages 449-460

  Atkinson, Richard L ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEPRAMONE; AMINOREX; ANTIDEPRESSANT AGENT; BENZOCAINE; DEXAMPHETAMINE; DEXFENFLURAMINE; DIGITALIS; DIURETIC AGENT; EPHEDRINE; FENFLURAMINE; FLUOXETINE; GROWTH HORMONE; LEPTIN; MAZINDOL; METHAMPHETAMINE; METHYLXANTHINE; OPIATE ANTAGONIST; PEPTIDE; PHENTERMINE; PHENYLPROPANOLAMINE; SEROTONIN AGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THYROID HORMONE; UNINDEXED DRUG;

AMNESIA; APPETITE; BEHAVIOR MODIFICATION; BODY WEIGHT; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DIET; DRUG ABUSE; DRUG MECHANISM; ENERGY BALANCE; ENERGY EXPENDITURE; FATIGUE; FOOD INTAKE; HUMAN; INSOMNIA; LIPOLYSIS; NONHUMAN; OBESITY; PULMONARY HYPERTENSION; SIDE EFFECT; SLEEP DISORDER; SWEATING; WEIGHT REDUCTION; XEROSTOMIA;

DIGITALIS;

EID: 0030670855     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb51854.x     Document Type: Conference Paper

References (58)

1. KUCZMARSKI, R. J., K. M. FLEGAL, S. M. CAMPBELL & C. L. JOHNSON. 1994. Increasing prevalence of overweight among US adults. JAMA 272: 205-211.
2. BRAY, G. A. 1976. The risks and disadvantages of obesity. In The Obese Patient, p. 215-251. Saunders. Philadelphia.
3. GRUNDY, S. M. & J. P. BARNETT. 1990. Metabolic and health complications of obesity. Dis. Mon. 36(12): 641-731.
4. SIMOPOULOS, A. P. & T. B. VAN ITALUE. 1984. Body weight, health, and longevity. Ann. Intern. Med. 100: 285-295.
5. PI-SUNYER, F. X. 1993. Medical hazards of obesity. Ann. Intern. Med. 119: 655-660.
6. BOUCHARD, C. & L. PERUSSE. 1993. Genetics of obesity. Annu. Rev. Nutr. 13: 337-354.
7. BOUCHARD, C. & L. PERUSSE. 1996. Current status of the human obesity gene map. Obes. Res. 4: 81-90.
8. ANDERSEN, T., K. H. STOKHOLM, O. G. BACKER & F. QUAADE. 1988. Long-term (5-year) results after either horizontal gastroplasty or very-low calorie diet for morbid obesity. Int. J. Obes. 12: 277-284.
9. KRAMER, F. M., R. W. JEFFERY, J. L. FORSTER & M. K. SNELL. 1989. Long-term follow-up of behavioural treatment for obesity: patterns of regain among men and women. Int. J. Obes. 13: 123-136.
10. WADDEN, T. A., J. A. STERNBERG, K. A. LETIZIA, A. J. STUNKARD & G. D. FOSTER. 1989. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int. J. Obes. 13(suppl. 2): 39-46.
11. PERRI, M. G. 1992. Improving maintenance of weight loss following treatment by diet and life-style modification. In Treatment of the Seriously Obese Patient, p. 456-477. Guilford Press. New York.
12. WILSON, G. T. 1993. Behavioral treatment of obesity: thirty years and counting. Adv. Behav. Res. Ther. 16: 31-75.
13. BRAY, G. A. 1991. Barriers to the treatment of obesity. Ann. Intern. Med. 115(2): 152-153.
14. WEINTRAUB, M. 1992. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin. Pharmacol. Ther. 51: 581-646.
15. WEINTRAUB, M., J. D. HASDAY, A. I. MUSHLIN & D. H. LOCKWOOD. 1984. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch. Intern. Med. 144: 1143-1148.
16. COLEMAN, D. L. 1978. Genetics of obesity in rodents. In Recent Advances in Obesity Research: II, p. 142-152. Newman. London.
17. ZHANG, Y., R. PROENCA, M. MAFFEI, M. BARONE, L. LEOPOLD & J. M. FRIEDMAN. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-431.
18. PELLEYMOUNTER, M. A., M. J. CULLEN, M. B. BAKER, R. HECHT, D. WINTERS, T. BOONE & F. COLLINS. 1995. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269: 540-543.
19. HALAAS, J. L., K. S. GAJIWALA, M. MAFFEI, S. L. COHEN, B. T. CHAIT, D. RABINOWITZ, R. L. LALLONE, S. K. BURLEY & J. M. FRIEDMAN. 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269: 543-546.
20. CAMPFIELD, L. A., F. J. SMITH, Y. CUISEZ, R. DEVOS & P. BURN. 1995. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269: 546-549.
21. LEVITSKY, D. A. & R. TROIANO. 1992. Metabolic consequences of fenfluramine for the control of body weight. Am. J. Clin. Nutr. 55: 167S-172S.
22. GRIFFITHS, R. R., J. V. BRADY & L. D. BRADFORD. 1979. Predicting the abuse liability of drugs with animal drug self-administration procedures: psychomotor stimulants and hallucinogens. Adv. Behav. Pharmacol. 2: 163-208.
23. BAEZ, M., J. D. KURSAR, L. A. HELTON, D. B. WAINSCOTT & D. L. G. NELSON. 1995. Molecular biology of serotonin receptors. Obes. Res. 3(suppl. 4): 441S-447S.
24. GOLDSTEIN, D. J., A. H. RAMPEY, JR., B. E. DORNSEIF, L. R. LEVINE, J. H. POTVIN & L. A. FLUDZINSKI. 1993. Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obes. Res. 1: 92-98.
25. RYAN, D. H., P. KAISER & G. A. BRAY. 1995. Sibutramine: a novel new agent for obesity treatment. Obes. Res. 3(suppl. 4): 553S-559S.
26. DRENT, M. L. & E. A. VAN DER VEEN. 1995. First clinical studies with orlistat: a short review. Obes. Res. 3(suppl. 4): 623S-625S.
27. BERGER, M. 1992. Pharmacological treatment of obesity: digestion and absorption inhibitors-clinical perspective. Am. J. Clin. Nutr. 55: 318S-319S.
28. CONSIDINE, R. V., M. K. SINHA, M. L. HEIMAN, A. KRIAUCIUNAS, T. W. STEPHENS, M. R. NYCE, J. P. OHANNESIAN, C. C. MARCO, L. J. MCKEE, T. L. BAUER & J. F. CARO. 1996. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334: 292-295.
29. SCOVILLE, B. A. 1976. Review of amphetamine-like drugs by the Food and Drug Administration. In Obesity in Perspective. Fogarty International Center for Advanced Studies in the Health Sciences, Series on Preventive Medicine, Vol. II, p. 441-443. U.S. Govt. Printing Office. Washington, District of Columbia.
30. SILVERSTONE, T. 1992. Appetite suppressants: a review. Drugs 43: 820-836.
31. GUY-GRAND, B., M. APFELBAUM, G. CREPALDI, A. CRIES, P. LEFEBVRE & P. TURNER. 1989. International trial of long-term dexfenfluramine in obesity. Lancet 2: 1142-1145.
32. MARKS, S. J., N. R. MOORE, M. L. CLARK, B. J. G. STRAUSS & T. D. R. HOCKADAY. 1996. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes. Res. 4: 1-7.
33. WILLEY, K. A., L. M. MOLYNEAUX, J. E. OVERLAND & D. K. YUE. 1992. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. Diabetes Med. 9:341-343.
34. MARCUS, M. D., R. R. WING, L. EWING, E. KERN, M. MCDERMOTT & W. GOODING. 1990. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am. J. Psychiatry 147: 876-881.
35. DARGA, L. L., L. CARROLL-MICHALS, S. J. BOTSFORD & C. P. LUCAS. 1991. Fluoxetine's effect on weight loss in obese subjects. Am. J. Clin. Nutr. 54: 321-325.
36. GOLDSTEIN, D. J. & J. H. POTVIN. 1994. Long-term weight loss: the effect of pharmacologic agents. Am. J. Clin. Nutr. 60: 647-657.
37. ATKINSON, R. L., F. L. GREENWAY, G. A. BRAY, W. T. DAHMS, M. E. MOLITCH, K. HAMILTON & J. RODIN. 1977. Treatment of obesity: comparison of physician and nonphysician therapists using placebo and anorectic drugs in a double-blind trial. Int. J. Obes. 1: 113-120.
38. GREENWAY, F. L. 1992. Clinical studies with phenylpropanolamine: a meta-analysis. Am. J. Clin. Nutr. 55(suppl. 1): 203S-205S.
39. ATKINSON, R. L., R. C. BLANK, J. F. LOPER, D. SCHUMACHER & R. A. LUTES. 1995. Combined treatment of obesity. Obes. Res. 3(suppl. 4): 497S-500S.
40. TOUBRO, S., A. V. ASTRUP, L. BREUM & F. QUAADE. 1993. Safety and efficacy of long-term treatment with ephedrine, caffeine, and an ephedrine/caffeine mixture. Int. J. Obes. 17(suppl. 1): S69-S72.
41. DALY, P. A., D. R. KRIEGER, A. G. DULLOO, J. B. YOUNG & L. LANDSBERG. 1993. Ephedrine, caffeine, and aspirin: safety and efficacy for treatment of human obesity. Int. J. Obes. 17(suppl. 1): S73-S78.
42. DULLOO, A. G. 1993. Ephedrine, xanthines, and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int. J. Obes. 17(suppl. 1): S35-S40.
43. ARNER, P. 1993. Adenosine, prostaglandins, and phosphodiesterase as targets for obesity pharmacotherapy. Int. J. Obes. 17(suppl. 1): S57-S59.
44. 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int. J. Obes. 19: 678-685.
45. DHURANDHAR, N. V., R. C. BLANK, D. SCHUMACHER, D. L. RITCH, E. CHAN, T. S. REIG & R. L. ATKINSON. 1995. Combination drug treatment of obesity in women of different ages. Obes. Res. 3(suppl. 3): 341S.
46. DHURANDHAR, N. V., R. C. BLANK, D. SCHUMACHER, D. L. RITCH, E. CHAN, T. S. RIEG & R. L. ATKINSON. 1995. Racial differences in response to combination drug treatment of obesity. Obes. Res. 3(suppl. 3): 405S.
47. HEUBERGER, R. A., J. LOPER, E. J. BALTES, R. LUTES, R. K. MAY, J. T. BROYLES & R. L. ATKINSON. 1995. VLCD followed by combination obesity drugs: results at one year. Obes. Res. 3(suppl. 3): 405S.
48. HARTLEY, G. G., S. NICOL, C. HALSTENSON, M. KHAN & A. PHELEY. 1995. Phentermine, fenfluramine, diet, behavior modification, and exercise for treatment of obesity. Obes. Res. 3(suppl. 3): 340S.
49. DHURANDHAR, N. V. & R. L. ATKINSON. 1996. Comparison of serotonin agonists in combination with phentermine for treatment of obesity. FASEB J. 10: A561.
50. RICAURTE, G. A., M. E. MOLLIVER, M. B. MARTELLO, J. L. KATZ, M. A. WILSON & A. L. MARTELLO. 1991. Dexfenfluramine neurotoxicity in brains of non-human primates. Lancet 338: 1487-1488.
51. MCCANN, U., G. HATZIDIMITRIOU, A. RIDENOUR, C. FISCHER, J. YUAN, J. KATZ & G. RICAURTE. 1994. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. Clin. Pharmacol. Exp. Then 269: 792-798.
52. BRENOT, F., P. HERVE, P. PETITPRETZ, F. PARENT, P. DUROUX & G. SIMONNEAU. 1993. Primary pulmonary hypenension and fenfluramine use. Br. Heart J. 70: 537-541.
53. SILVERSTONE, J. T. & T. SOLOMON. 1965. The long-term management of obesity in general practice. Br. J. Clin. Pract. 19: 395-398.
54. ENZI, G., A. BARITUSSIO, E. MARCHIORI & G. CREPALDI. 1976. Short-term and long-term clinical evaluation of a non-amphetamine anorexiant (mazindol) in the treatment of obesity. J. Int. Med. Res. 4: 305-317.
55. INOUE, S., M. EGAWA, S. SATOH, M. SAITO, H. SUZUKI, Y. KUMAHARA, M. ABE, A. KUMAGAI, Y. GOTO, K. SHIZUME, N. SHIMIZU, C. NAITO & T. ONISHI. 1992. Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan. Am. J. Clin. Nutr. 55:199S-202S.
56. HUDSON, K. D. 1977. The anorectic and hypotensive effect of fenfluramine in obesity. J. R. Coll. Gen. Pract. 27: 497-501.
57. TAUBER-LASSEN, E., P. DAMSBO, J. E. HENRIKSEN, B. PALMVIG & H. BECK-NIELSEN. 1990. Improvement of glycemic control and weight loss in type 2 (non-insulin-dependent) diabetics after one year of dexfenfluramine treatment. Diabetologia 33(suppl.): A124.
58. MATHUS-VUEGEN, E. M. H., K. VAN DE VOORE, A. M. E. KOK & A. M. A. RES. 1992. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake, and eating behavior. J. Intern. Med. 232: 119-127.